How megatrends can help fuel growth in an economic recovery

Is there potential to exceed benchmarks if companies focus on digital transformation, healthcare innovation and sustainability?

Is there potential to exceed benchmarks if companies focus on digital transformation, healthcare innovation and sustainability?

Market analysts generally agree that three major megatrends sweeping the globe—digital transformation, healthcare innovation and sustainability—are going to fuel high growth rates in those companies that successfully take advantage of these developments.

Already, companies are delivering against these earnings growth expectations. But we take it a step further: we think that megatrend beneficiaries may not only continue to outperform slower-growing counterparts but also may do even better than current consensus projections.


Our major findings

Generally, we believe that today’s earnings estimates do not yet capture the additional upside we think is likely to come from these new investment opportunities as new revenue streams go from concept to reality.

More specifically, we think investors are underestimating the potential in:

  • Technology—the value of the new revenue streams that 5G and artificial intelligence (AI) are offering. Already, we see evidence that COVID-19 is accelerating adoption of key technologies, such as cloud computing and, with it, cloud security and AI. Currently, Nasdaq Computer Index 2019⁠–⁠2022 earnings growth is forecast at approximately 10%. But we believe that neither 5G’s $700 billion revenue opportunity nor AI’s $16 trillion opportunity that are likely to begin to materialize in the next five years are priced into stock values—yet.
  • Healthcare—the confluence of data and gene-based technologies, as well as a recent pick-up in biotech R&D, that may speed up new molecule approvals and therefore may help increase earnings growth. While innovation in healthcare is not new, today’s speed is. We expect the increasing pace of new treatment approvals in the next five years could yield $255 billion of additional revenues by 2024. If half of that accrues to biotech companies, the revenues of Nasdaq Biotech could almost double from current levels. So, while consensus projections see a 27% earnings growth rate for healthcare, we expect greater growth because, typically, analysts do not recognize the full value of future sales until they are a reality.
  • Sustainability—the speed of the move toward sustainable economies, which is increasingly dictated by favorable economics. Clean energy earnings are projected to grow 17% from 2019–⁠2022. But, much like digital transformation and AI, the move to sustainable investments is still very early in its life cycle. And while the immense opportunity has been well-telegraphed, a historical look at forecasts reveals consistent underestimations of both capacity build and generation.


What drives outperformance?

We find that the most significant factor driving outperformance versus benchmark is a sector’s expected earnings growth rate. It was the sectors and stocks with higher expected growth rates that outperformed over the past 20 years, despite valuation fluctuations and earnings revisions.

For example, since 2001, technology and biotech (the S&P 500 sectors responsible for a large portion of innovation and whose earnings growth rates outpaced the index) have cumulatively outperformed the SPX by 103% and 357%, respectively.1

Tech and biotech have cumulatively (though not always consistently) outperformed over the past two decades

The bar chart shows a comparison of the average annual performance over a variety of time periods in the past two decades for SPX, tech, and biotech. The chart shows that tech and biotech have cumulatively outperformed the SPX over the past two decades, although they have not outperformed in every time frame.


Another determining factor appears to be how much investors are willing to pay (in multiples) for expectations of growth in earnings. When the willingness fluctuates, it can detract from performance. Still, the most significant factor driving outperformance was a high starting point for earnings. So it pays to look at those sectors, subsectors and companies that have high growth rates. What we find: the earnings growth for tech, biotech and clean energy indices is projected to run at a double-digit pace, well ahead of the S&P 500. See below.


Expectations are high for tech, biotech and clean energy

The bar chart shows the 2019-2022 EPS CAGR for the SPX, Nasdaq Computer, Global Clean Energy, and Nasdaq Biotech. The SPX has the lowest EPS CAGR for this time frame, showing that expecations are high for tech, biotech, and clean energy.


How do you find potential winners?

Given our high performance expectations, how do we propose identifying investments that could benefit from the megatrends? We see three paths:

  1. Sector—Identify emerging trends within each sector likely to have earnings growth rates that are above the average
  2. Company—Analyze companies’ fundamentals and growth drivers to select those likely to surprise to the upside
  3. Private opportunity—Invest in largely undiscovered private companies before they go public and become widely recognized

It will take a lot of research, analysis and monitoring to stay on top of the global megatrends and spot the right companies. We invite you to speak with your J. P. Morgan team to hear our latest insights into opportunities and how megatrends investing might fit into your overall wealth plan.

1. From 2001 to 2005 the average annual performance of tech trailed the SPX. Yet tech has been a consistent outperformer since 2006. In particular, it has substantially widened its outperformance since 2016. Biotech’s track record has been spottier. While it outperformed on average, a lot of that outperformance occurred from 2011 to 2015. Since 2016, its average returns have been lackluster.





Important Information

This material is for informational purposes only, and may inform you of certain products and services offered by J.P. Morgan’s wealth management businesses, part of JPMorgan Chase & Co. (“JPM”). Please read all Important Information.

All market and economic data is as of May 2020 and sourced from Bloomberg Finance L.P. or Factset unless otherwise stated.



Any views, strategies or products discussed in this material may not be appropriate for all individuals and are subject to risks. Investors may get back less than they invested, and past performance is not a reliable indicator of future results. Asset allocation does not guarantee a profit or protect against loss. Nothing in this material should be relied upon in isolation for the purpose of making an investment decision. You are urged to consider carefully whether the services, products, asset classes (e.g., equities, fixed income, alternative investments, commodities, etc.) or strategies discussed are suitable to your needs. You must also consider the objectives, risks, charges, and expenses associated with an investment service, product or strategy prior to making an investment decision. For this and more complete information, including discussion of your goals/situation, contact your J.P. Morgan representative.

Private investments are subject to special risks. Individuals must meet specific suitability standards before investing. This information does not constitute an offer to sell or a solicitation of an offer to buy . As a reminder, hedge funds (or funds of hedge funds), private equity funds, real estate funds often engage in leveraging and other speculative investment practices that may increase the risk of investment loss. These investments can be highly illiquid, and are not required to provide periodic pricing or valuation information to investors, and may involve complex tax structures and delays in distributing important tax information. These investments are not subject to the same regulatory requirements as mutual funds; and often charge high fees. Further, any number of conflicts of interest may exist in the context of the management and/or operation of any such fund. For complete information, please refer to the applicable offering memorandum. Securities are made available through J.P. Morgan Securities LLC, Member FINRA, and SIPC, and its broker-dealer affiliates.


The NASDAQ Computer Index contains securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as Technology excluding Telecommunications Equipment. They include computer services, internet, software, computer hardware, electronic office equipment, and semiconductors.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).

The SPX (S&P 500 Index or the Standard & Poor's 500 Index) is a market-capitalization-weighted index of the 500 largest U.S. publicly traded companies.

The S&P 500® Information Technology comprises those companies included in the S&P 500 that are classified as members of the GICS® information technology sector.

The S&P 500 Biotechnology and Industry Index comprises stocks in the S&P Total Market Index that are classified in the GICS biotechnology sub-industry.

The iShares Global Clean Energy ETF seeks to track the S&P Global Clean Energy Index.


Certain information contained in this material is believed to be reliable; however, JPM does not represent or warrant its accuracy, reliability or completeness, or accept any liability for any loss or damage (whether direct or indirect) arising out of the use of all or any part of this material. No representation or warranty should be made with regard to any computations, graphs, tables, diagrams or commentary in this material, which are provided for illustration/reference purposes only. The views, opinions, estimates and strategies expressed in this material constitute our judgment based on current market conditions and are subject to change without notice. JPM assumes no duty to update any information in this material in the event that such information changes. Views, opinions, estimates and strategies expressed herein may differ from those expressed by other areas of JPM, views expressed for other purposes or in other contexts, and this material should not be regarded as a research report. Any projected results and risks are based solely on hypothetical examples cited, and actual results and risks will vary depending on specific circumstances. Forward-looking statements should not be considered as guarantees or predictions of future events.

Nothing in this document shall be construed as giving rise to any duty of care owed to, or advisory relationship with, you or any third party. Nothing in this document shall be regarded as an offer, solicitation, recommendation or advice (whether financial, accounting, legal, tax or other) given by J.P. Morgan and/or its officers or employees, irrespective of whether or not such communication was given at your request. J.P. Morgan and its affiliates and employees do not provide tax, legal or accounting advice. You should consult your own tax, legal and accounting advisors before engaging in any financial transactions.  


Conflicts of interest will arise whenever JPMorgan Chase Bank, N.A. or any of its affiliates (together, “J.P. Morgan”) have an actual or perceived economic or other incentive in its management of our clients’ portfolios to act in a way that benefits J.P. Morgan. Conflicts will result, for example (to the extent the following activities are permitted in your account): (1) when J.P. Morgan invests in an investment product, such as a mutual fund, structured product, separately managed account or hedge fund issued or managed by JPMorgan Chase Bank, N.A. or an affiliate, such as J.P. Morgan Investment Management Inc.; (2) when a J.P. Morgan entity obtains services, including trade execution and trade clearing, from an affiliate; (3) when J.P. Morgan receives payment as a result of purchasing an investment product for a client’s account; or (4) when J.P. Morgan receives payment for providing services (including shareholder servicing, recordkeeping or custody) with respect to investment products purchased for a client’s portfolio. Other conflicts will result because of relationships that J.P. Morgan has with other clients or when J.P. Morgan acts for its own account.

Investment strategies are selected from both J.P. Morgan and third-party asset managers and are subject to a review process by our manager research teams. From this pool of strategies, our portfolio construction teams select those strategies we believe fit our asset allocation goals and forward-looking views in order to meet the portfolio’s investment objective.

As a general matter, we prefer J.P. Morgan managed strategies. We expect the proportion of J.P. Morgan managed strategies will be high (in fact, up to 100 percent) in strategies such as cash and high-quality fixed income, subject to applicable law and any account-specific considerations.

While our internally managed strategies generally align well with our forward-looking views, and we are familiar with the investment processes as well as the risk and compliance philosophy of the firm, it is important to note that J.P. Morgan receives more overall fees when internally managed strategies are included. We offer the option of choosing to exclude J.P. Morgan managed strategies (other than cash and liquidity products) in certain portfolios.

The Six Circles Funds are U.S.-registered mutual funds managed by J.P. Morgan and sub-advised by third parties. Although considered internally managed strategies, JPMC does not retain a fee for fund management or other fund services. 


In the United States, bank deposit accounts and related services, such as checking, savings and bank lending, are offered by JPMorgan Chase Bank, N.A. Member FDIC.

JPMorgan Chase Bank, N.A. and its affiliates (collectively “JPMCB”) offer investment products, which may include bank-managed investment accounts and custody, as part of its trust and fiduciary services. Other investment products and services, such as brokerage and advisory accounts, are offered through J.P. Morgan Securities LLC (“JPMS”), a member of FINRA and SIPC. Annuities are made available through Chase Insurance Agency, Inc. (CIA), a licensed insurance agency, doing business as Chase Insurance Agency Services, Inc. in Florida. JPMCB, JPMS and CIA are affiliated companies under the common control of JPMorgan Chase & Co. Products not available in all states.

References to “J.P. Morgan” are to JPM, its subsidiaries and affiliates worldwide. “J.P. Morgan Private Bank” is the brand name for the private banking business conducted by JPM.

This material is intended for your personal use and should not be circulated to or used by any other person, or duplicated for nonpersonal use, without our permission. If you have any questions or no longer wish to receive these communications, please contact your J.P. Morgan representative. 

© 2020 JPMorgan Chase & Co. All rights reserved.


Check the background of Our Firm and Investment Professionals on FINRA's BrokerCheck

To learn more about J. P. Morgan’s investment business, including our accounts, products and services, as well as our relationship with you, please review our  J.P. Morgan Securities LLC Form CRS and  Guide to Investment Services and Brokerage Products.

This website is for informational purposes only, and not an offer, recommendation or solicitation of any product, strategy service or transaction. Any views, strategies or products discussed on this site may not be appropriate or suitable for all individuals and are subject to risks. Prior to making any investment or financial decisions, an investor should seek individualized advice from a personal financial, legal, tax and other professional advisors that take into account all of the particular facts and circumstances of an investor's own situation. 

This website provides information about the brokerage and investment advisory services provided by J.P. Morgan Securities LLC (“JPMS”). When JPMS acts as a broker-dealer, a client's relationship with us and our duties to the client will be different in some important ways than a client's relationship with us and our duties to the client when we are acting as an investment advisor. A client should carefully read the agreements and disclosures received (including our Form ADV disclosure brochure, if and when applicable) in connection with our provision of services for important information about the capacity in which we will be acting.

Equal Housing Opportunity logo

J.P. Morgan Chase Bank N.A., Member FDIC Not a commitment to lend. All extensions of credit are subject to credit approval 

“J.P. Morgan Securities” is a brand name for a wealth management business conducted by JPMorgan Chase & Co. (“JPMC”) and its subsidiaries worldwide. JPMorgan Chase Bank, N.A. and its affiliates (collectively “JPMCB”) offer investment products, which may include bank managed accounts and custody, as part of its trust and fiduciary services. Other investment products and services, such as brokerage and advisory accounts, are offered through J.P. Morgan Securities LLC (“JPMS”), a member of FINRA and SIPC. Annuities are made available through Chase Insurance Agency, Inc. (CIA), a licensed insurance agency, doing business as Chase Insurance Agency Services, Inc. in Florida. JPMCB, JPMS and CIA are affiliated companies under the common control of JPMorgan Chase & Co. Products not available in all states.

Please read additional Important Information in conjunction with these pages.